AUROBINDO PHARMA
|
|
| BOM : 524804 NSE : AUROPHARMA | |
| LT :
Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
| ST :
Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Apr 04,2025 |
|
Price(EOD): ₹ 1,104.80
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 64,166.78 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| AUROBINDO PHARMA | -4.7% | 5% | 6.9% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.5% | 9.1% | 9.1% |
| DIVIS LABORATORIES | -4.9% | -0.6% | 59.1% |
| CIPLA | -1.8% | 1% | 0.5% |
| TORRENT PHARMACEUTICALS | 1.6% | 12.1% | 21.8% |
| DR REDDYS LABORATORIES | -3% | -0.9% | -7.7% |
| MANKIND PHARMA | 1.1% | 7.6% | 1.3% |
| ZYDUS LIFESCIENCES | -2.2% | -0.6% | -9.3% |
| LUPIN | -2.7% | 1% | 30.1% |
FUNDAMENTAL ANALYSIS OF AUROBINDO PHARMA
[ Q(TTM): Dec2024, Y: Mar2024
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF AUROBINDO PHARMA
[As on : Apr 04,2025
]
| Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
18.33
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 3,500.25 Cr
[Latest Qtr - Dec2024 - Consolidated Results ] 2.15
P/B Calculated based on Book Value of Rs 29,842.80 Cr
[Latest Year - Mar2024 - Consolidated Results ] 2.08
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 30,921.80 Cr
[Latest Qtr - Dec2024 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
25% -15% -10% |
SHARE PRICE MOMENTUM OF AUROBINDO PHARMA
AUROBINDO PHARMA vs SENSEX
DEBT OF AUROBINDO PHARMA
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2024 2023 2022 Avg_3yrs |
0.14 0.23 0.11 0.16 |
0.21 0.18 0.1 0.16 |
|
[Last Annual Data : Mar2024]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF AUROBINDO PHARMA
| Pledged Promoter Shares |
17.83 % | |
|---|---|---|
| As on : Dec2024 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF AUROBINDO PHARMA
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
2.34% 0.76% -0.74% 3.35% |
8.53% -1.46% -5.28% -10.46% |
| QtrlyTrend |
0 | |
| Latest Qtr: Dec2024 | ||
| Quarterly Result Analysis → | ||
AUROBINDO PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE MIDSMALLCAP | 1.4% | 9.3% | 8.2% |
| BSE LARGEMIDCAP | -0.4% | 6.4% | 3.7% |
| BSE ALLCAP | -0.8% | 4.8% | 5.8% |
| BSE 500 SHARIAH | -1.2% | 5% | -1.8% |
| BSE HEALTHCARE | -2.3% | 5.7% | 14.3% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDCAP 100 | -2.3% | 5.6% | 3.5% |
| NIFTY HEALTHCARE INDEX | -2.3% | 5.4% | 10.2% |
| NIFTY MIDSMALL HEALTHCARE | -2.3% | 6.5% | 20.3% |
| NIFTY 500 EQUAL WEIGHT | -2.4% | 6.4% | NA |
| NIFTY MIDCAP 50 | -2.4% | 4.7% | 3.4% |
You may also like the below Video Courses
FAQ about AUROBINDO PHARMA
Is AUROBINDO PHARMA good for long term investment?
As on Apr 04,2025, the Fundamentals of AUROBINDO PHARMA look Strong and hence it may be good for long term investment! See Financial Performance of AUROBINDO PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is AUROBINDO PHARMA UnderValued or OverValued?
As on Apr 04,2025, AUROBINDO PHARMA is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of AUROBINDO PHARMA ?
As on Apr 04,2025, the Intrinsic Value of AUROBINDO PHARMA is Rs. 1,227.56 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 884.14
Fair Value [Median EV / Sales Model] : Rs. 1,297.68
Fair Value [Median Price / Sales Model] : Rs. 1,227.56
Estimated Median Fair Value of AUROBINDO PHARMA : Rs. 1,227.56
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
